3.13
0.00 (0.00%)
| Penutupan Terdahulu | 3.13 |
| Buka | 3.13 |
| Jumlah Dagangan | 6,694,912 |
| Purata Dagangan (3B) | 11,115,979 |
| Modal Pasaran | 805,761,984 |
| Harga / Pendapatan (P/E Ke hadapan) | 4.64 |
| Harga / Jualan (P/S) | 1.66 |
| Harga / Buku (P/B) | 98.42 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 4 Aug 2026 |
| Margin Keuntungan | -59.03% |
| Margin Operasi (TTM) | -34.00% |
| EPS Cair (TTM) | -0.850 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | -52.80% |
| Nisbah Semasa (MRQ) | 1.18 |
| Aliran Tunai Operasi (OCF TTM) | -100.11 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -80.85 M |
| Pulangan Atas Aset (ROA TTM) | -7.17% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Drug Manufacturers - Specialty & Generic (US) | Bercampur | Menaik |
| Drug Manufacturers - Specialty & Generic (Global) | Bercampur | Menaik | |
| Stok | Esperion Therapeutics, Inc. | Menurun | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | -0.5 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | 4.0 |
| Purata | 0.38 |
|
Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C. |
|
| Sektor | Healthcare |
| Industri | Drug Manufacturers - Specialty & Generic |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 0.57% |
| % Dimiliki oleh Institusi | 59.40% |
| Julat 52 Minggu | ||
| Median | 5.00 (59.74%) | |
| Jumlah | 1 Beli | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Needham | 03 Mar 2026 | 5.00 (59.74%) | Beli | 2.91 |
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |